FDA sends CRL to Outlook Therapeutics for ONS-5010 resubmission | Optometry Times - Clinical News

Published on January 2, 2026
The FDA issued a CRL for ONS-5010, citing the need for additional confirmatory efficacy evidence despite previous trials showing efficacy, according to the company.
Continue reading on website
Other news

A new treatment round-up for AMD and GA | Optometry Times - Clinical News

January 2, 2026
Knowing what’s on the market for AMD and GA aids in preserving vision.

FDA extends Aldeyra's reproxalap PDUFA after requesting additional clinical study report | Optometry Times - Clinical News

January 3, 2026
Aldeyra met with the FDA on December 12, 2025, in which the FDA requested the company submit the CSR from the reproxalap dry eye disease field trial to the NDA.